Clinical significance of peripheral blood UL16 and DR-70 for the early diagnosis and prognostic evaluation of colorectal cancer

Table 1 Comparison of serum UL16-binding protein 2 and DR-70 levels among the colorectal cancer, benign, and control groups, mean ± SD

Group	ULBP2 (ng/L)	DR-70 (μg/mL)
CRC (n = 60)	84.28 ± 13.52a	1.28 ± 0.41a
Benign (n = 50)	68.04 ± 8.89	0.48 ± 0.15
Control (n = 50)	66.93 ± 9.15	0.46 ± 0.14
F value	44.392	161.273
P value	< 0.001	< 0.001

^aP < 0.05 compared with the control and benign groups.

ULBP2: UL16-binding protein 2; CRC: Colorectal cancer.

Table 2 Comparison of serum UL16-binding protein 2 and DR-70 levels among patients with different prognostic outcomes, mean ± SD

Group	ULBP2 (ng/L)	DR-70 (μg/mL)
Good prognosis (n = 43)	76.91 ± 15.28	1.10 ± 0.36
Poor prognosis (n = 17)	95.67 ± 17.05	1.49 ± 0.45
t value	4.147	3.518
P value	0.001	0.001

ULBP2: UL16-binding protein 2.

Table 3 Diagnostic values of different indicators for early-stage colorectal cancer

Index	AUC	Sensitivity (%)	Specificity (%)	Youden's index	SE	95%CI
ULBP2	0.743	84.00	65.00	0.490	0.0472	0.651-0.821
DR-70	0.725	90.00	53.33	0.433	0.0477	0.632-0.806
ULBP2 combined with DR-70	0.952	92.00	86.67	0.767	0.0178	0.894-0.984

ULBP2: UL16-binding protein 2; AUC: Area under the curve.

Table 4 Diagnostic values of different indicators for poor prognosis of colorectal cancer

Index	AUC	Sensitivity (%)	Specificity (%)	Youden's index	SE	95%CI
ULBP2	0.731	76.50	76.70	0.532	0.0807	0.600–0.837
DR-70	0.748	64.71	81.40	0.495	0.0782	0.619–0.851
ULBP2 combined with DR-70	0.885	82.35	88.37	0.648	0.0485	0.776–0.953

ULBP2: UL16-binding protein 2; AUC: Area under the curve.